Name of the Procedure:

Injection, mogamulizumab-kpkc, 1 mg

Common Names:

• Mogamulizumab Injection
• Moga Injection

Technical/Medical Term:

• HCPCS Code: J9204

Summary

Mogamulizumab is a medication used to treat certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) and Sézary syndrome. It is given as an injection into a vein and helps target cancer cells directly.

Purpose

Mogamulizumab is used to:

• Treat cutaneous T-cell lymphoma (CTCL) and Sézary syndrome.
• Reduce the number of cancerous cells in the body.
• Improve symptoms and slow down disease progression.

Indications

Mogamulizumab injections are indicated for patients who:

• Have been diagnosed with CTCL or Sézary syndrome.
• Have not responded to other treatments.
• Have disease progression despite previous therapy.

Preparation

Before receiving the injection, patients may be advised to:

• Discuss all current medications with their healthcare provider.
• Undergo blood tests to check overall health and liver function.
• Inform the doctor about any existing medical conditions or allergies.

Procedure Description

1. Preparation: The healthcare provider prepares the mogamulizumab solution.
2. IV Access: A needle is inserted into a vein, usually in the arm.
3. Injection: The mogamulizumab solution is administered slowly through the IV.
4. Monitoring: Vital signs are monitored before, during, and after the injection to ensure no adverse reactions occur.

Tools and Equipment:

• IV needle and catheter
• Mogamulizumab solution
• Monitoring equipment for vital signs

Anesthesia:

• No anesthesia or sedation is typically required.

Duration

• The administration of mogamulizumab typically takes around 60 minutes.

Setting

• This procedure is usually performed in a hospital outpatient clinic or a specialized infusion center.

Personnel

• An oncologist or hematologist
• Registered nurses
• Medical assistants or technicians

Risks and Complications

Common Risks:

• Infusion reactions (fever, chills, rash)
• Fatigue
• Nausea

Rare Risks:

• Severe allergic reactions
• Infections
• Liver dysfunction

Possible complications are managed with medication or supportive care as needed.

Benefits

• Reduction in cancerous cell count
• Alleviation of symptoms related to CTCL and Sézary syndrome
• Potential to slow or halt disease progression

Benefits may be noticed within a few weeks to months of starting treatment.

Recovery

• Patients can usually resume normal activities shortly after the injection.
• Regular follow-up appointments to monitor health and treatment effectiveness.
• Instructions might include monitoring for side effects and contacting the doctor if severe symptoms appear.

Alternatives

Alternative treatments for CTCL and Sézary syndrome include:

• Other chemotherapy drugs
• Radiation therapy
• Stem cell transplants

Each alternative has its own pros and cons, such as effectiveness, side effects, and overall impact on quality of life.

Patient Experience

During the procedure, patients may feel a slight pinch when the IV needle is inserted and some mild discomfort during the injection. Post-procedure, mild fatigue or infusion reactions are possible but usually manageable with medication and rest. Pain management includes over-the-counter pain relief medications if necessary.